Nitroaspirin

Nitroaspirin (NCX 4016) is a nitric oxide (NO) donor and a nitro-derivative of Aspirin, which combines with Nitroaspirin to inhibit cyclooxygenase. Nitroaspirin (NCX 4016) has antithrombotic and anti-platelet properties and acts as a direct and irreversible inhibitor of COX-1. Nitroaspirin (NCX 4016) causes significant induction of cell cycle arrest and apoptosis in Cisplatin-resistant human ovarian cancer cells via down-regulation of EGFR/PI3K/STAT3 signaling and modulation of Bcl-2 family proteins[1][2][3][4].

Product Specifications

CAS Number

[175033-36-0]

Product Name Alternative

NCX 4016

UNSPSC

12352005

Target

Apoptosis; COX

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nitroaspirin.html

Concentration

10mM

Purity

98.57

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

O=C(OC1=CC=CC(CO[N+]([O-])=O)=C1)C2=CC=CC=C2OC(C)=O

Molecular Formula

C16H13NO7

Molecular Weight

331.28

References & Citations

[1]Bertuglia S, et al. Antioxidant activity of nitro derivative of aspirin against ischemia-reperfusion in hamster cheekpouch microcirculation. Am J Physiol Gastrointest Liver Physiol. 2004 Mar;286 (3) :G437-43.|[2]Corazzi T, et al. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016) . J Pharmacol Exp Ther. 2005 Dec;315 (3) :1331-7.|[3]Selvendiran K, et al. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cell Cycle. 2008 Jan 1;7 (1) :81-8.